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cytes, neutrophils, mastocytes, T-lymphocytes, fi broblasts 
and macrophages.
Disorders that may benefi t from such approach are nu-
merous, with psoriasis, atopic dermatitis, cutaneous T-cell 
lymphomas, morphea, and vitiligo as main indications.
Currently, phototherapy with broadband UVB (290–
320 nm), narrowband UVB (311–313 nm), 308 nm excimer 
laser, UVA 1 (340–400 nm), UVA plus psoralen (PUVA), 
Phototherapy presents a physical form of treatment 
which uses an artifi cial ultraviolet (UV) radiation of dif-
ferent wavelenghts emitted from fl uorescent lamps (with 
or without adding the photosensitiser) in the management 
of several dermatoses. UV radiation makes only 10% of 
the entire electromagnetic spectrum (200–400 nm). It is 
the biologically most potent part of the sunlight spectrum. 
UV light affects almost all epidermal and dermal cells: 
keratinocytes, Langerhans cells, endothelium, melano-
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A B S T R A C T
Phototherapy is a second-line treatment modality for the most common dermatoses that is safe and effective. Most 
phototherapy regimens denote the use of ultraviolet (UV) radiation of different wavelengths in the management of sev-
eral dermatoses. Currently, irradiations with broadband UVB (290–320 nm), narrowband UVB (311–313 nm), 308 nm 
excimer laser, UVA 1 (340–400 nm), UVA with psoralen (PUVA), and extracorporeal photochemotherapy (photopheresis) 
are being used. Benefi cial effects of UV radiation are far from being completely understood. Dermatoses that may benefi t 
from such approach are numerous, with psoriasis, parapsoriasis, atopic dermatitis, cutaneous T-cell lymphomas, morphea, 
and vitiligo vulgaris as main indications. UVB radiation primarily acts on cells at the epidermis and the epidermodermal 
junction, while UVA radiation affects epidermal and dermal components, especially blood vessels. UV radiation has im-
mediate and delayed effects. Immediate effects are the formation of DNA photoproducts and DNA damage leading to 
apoptosis of keratinocytes, Langerhans cells, activated T-lymphocytes, neutrophils, macrophages, NK cells, fi broblasts, 
endothelial cells, and mast-cells, cell membrane damage by lipid peroxidation, and isomerization of chromophores such 
as urocanic acid. Delayed effects include synthesis of prostaglandins and cytokines that play important roles in immune 
suppression. Systemic and local immune suppression, alteration in cytokine expression (induction of interleukin-1 (IL-1) 
receptor antagonist, decrease in IL-2, increase in IL-10, IL-15), and cell cycle arrest may all contribute to the suppression 
of disease activity. PUVA is a form of controlled and repeated induction of phototoxic reactions which uses UVA light to 
activate chemicals known as psoralens. The conjunction of psoralens with epidermal DNA inhibits DNA synthesis and 
causes cell apoptosis. PUVA also causes an alteration in the expression of cytokines and cytokine receptors. Psoralens 
interact with RNA, proteins and other cellular components and indirectly modify proteins and lipids via singlet oxygen-
mediated reactions or by generating of free radicals. Psoralens and UV radiation also stimulate melanogenesis with 
variable effects in patients with vitiligo vulgaris. Extracorporeal photopheresis is treatment modality used in management 
of erythrodermic cutaneous T-cell lymphomas. It is very potent in induction of lymphocyte apoptosis. Despite the introduc-
tion of numerous potent bioengineered systemic medications in the fi eld of dermatology, phototherapy remains established, 
and often preferred, option for the most common dermatoses.
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and extracorporeal photochemotherapy (photopheresis) 
are being used1.
The interplay of the various photobiologic pathways is 
far from being completely understood.
Ultraviolet B Therapy
According to the European protocol, UVB is the sim-
plest form of phototherapy, as it refers to the use of artifi -
cial UVB radiation without additional exogenous photo-
sensitizers. UVB radiation primarily penetrates into 
structures of the epidermis and superfi cial dermis2.
The radiation is absorbed by the major endogenous 
chromophores with immunological importance, such as 
nuclear DNA, trans-urocanic acid, and cell membranes1.
After UVB light absorption by nucleotides, covalent 
bonds start to form between two pyrimidine bases (thy-
mine-thymine, cytosine-thymine, cytosine-cytosine rar-
est) and cyclobutane ring is created which causes growth 
arrest in keratinocytes, reversing epidermal acanthosis. 
This is the basic mechanism when treating psoriasis, 
parapsoriasis, pityriasis lichenoides chronica which have 
a signifi cantly accelerated keratinocyte proliferation.
After single exposure, UVB light already upregulates 
expression of tumor suppressor gene p53. Affected under 
p53, individual keratinocytes will stop the cell cycle in G1 
phase in order to facilitate DNA repair (pyrimidine dimer 
excision) before the cell enters into S phase of cell cycle 
(DNA replication occurs during this phase). Unless py-
rimidine dimers are excised, individual keratinocytes 
undergo apoptosis (»sunburn cells«). It remains unknown 
why certain keratinocytes are more sensitive to UV ra-
diation than others (senescent keratinocytes are more 
resistant to apoptosis than young keratinocytes)3. The 
upregulation of this tumor suppressor gene may be respon-
sible for inhibition of keratinocyte turnover in psoriatic 
plaques4.
UVB light causes photoisomerization of urocanic acid 
(UCA), another important chromophore within the stra-
tum corneum of the epidermis. Upon UVB exposure, UCA 
is converted from trans-UCA to cis-UCA5. The presence of 
cis-UCA has local and systemic immunosuppressive ef-
fects via cutaneous cytokine modulation6. cis-UCA down-
regulates interleukin (IL)-12 (one of the crucial Th1 cyto-
kines) production and enhances CD4+ T-cell IL-10 
production, which could account for some of the immuno-
suppressive effects of UV radiation. Exposure of Langer-
hans cells to cis-UCA inhibits their ability to present an-
tigen and induces immunosuppression.
Direct damage of DNA and accumulation of cis-UCA 
induce formation of reactive oxygen species and free radi-
cals that can affect extranuclear molecular targets located 
in the cytoplasm and cell membane. These targets include 
cell surface receptors for epidermal growth factor (EGF), 
IL-1, and tumor necrosis factor (TNF), kinases, phospha-
tases, and transcription factors such as activator protein-1 
(AP-1) and nuclear factor-kappa B (NF-kB). Devary et al. 
have found that UV response does not require a nuclear 
signal and is likely to be initiated at the plasma mem-
brane. Lipid peroxidation of cell membrane may lead to 
activation of Src tyrosine kinases, which subsequently 
activate a cascade involving Ha-Ras, Raf-1, and JNK lead-
ing to the phosphorylation of c-jun and activation of the 
transcription factors AP-1 and NF-kB. Activation of NF-
kB at the cell membrane following UVB exposure leads to 
T- lymphocytes apoptosis, which requires de novo protein 
synthesis, and increased membrane permeability which 
may also play a role in immunosuppression7.
In addition to its effect on the cell cycle, UV light in-
duces the release of prostaglandins and cytokines. Follow-
ing UVB exposure, keratinocytes and lymphocytes secrete 
a number of pro-infl ammatory cytokines such as IL-1, IL-
10, and TNF-a, which suppress Langerhans cells and 
thereby induce immunosuppression8. Several cytokines 
with important role in immune suppression, such as IL-6, 
IL-8, IL-10, IL-15, granulocyte-macrophage colony-stim-
ulating factor (GM-CSF) and prostaglandins, are released 
from UV-irradiated keratinocytes. Prostaglandin E2 
(PGE2) is a potent mediator that inhibits the expression 
of co-stimulatory molecules on the surface of antigen-pre-
senting cells and thereby prevents the activation of T-lym-
phocytes.
Keratinocytes and lymphocytes also upregulate Fas/
FasL expression following UVB exposure and caspases 
are activated, resulting in nuclear DNA fragmentation 
and degradation of cellular structural proteins – laminin 
and actin.
Langerhans cells, the most important epidermal anti-
gen-presenting cells, are highly susceptible to UVB irra-
diation, which reduces their number and alters their an-
tigen-presenting function. Langerhans cells with altered 
antigen-presentig capacity leave the skin lesions and re-
sult in diminished response in the lymph node, which 
down-regulates systemic immune activation. The remain-
ing dendritic cells acquire cytoskeleton damage by oxida-
tive stress, and this reduces their ability to express high 
numbers of costimulatory surface markers to effi ciently 
stimulate T cells. This mechanism has been proven to be 
effective in treatment of atopic dermatitis and cell-medi-
ated (type IV) contact dermatitis. UVB exerts its action 
through direct phototoxic effect on T-lymphocytes in the 
dermoepidermal junction in patients with atopic dermati-
tis1. Interestingly, UVB is also effective in suppression of 
Staphylococcus aureus colonization in atopic dermatitis9. 
UVB can selectively reduce proinfl ammatory cytokine 
production in individual T cells, inhibiting Th-1 axis by 
IL-12, interferon-g (IFN-g) and IL-8, which has a benefi -
cial effect in psoriasis characterized by intraepidermal 
and perivascular T-cell infi ltrates in the papillary der-
mis10. Another effect of phototherapy is its ability to re-
verse pathologic vessel architecture in psoriasis plaques 
and bring the elongated and tortuous capillary loops back 
to normal state.
UVB is effective in apoptosis of neutrophils, the major 
pathologic cells in Munro’s microabscess of pustular pso-
riasis. Decreased expression of the adhesion molecules on 
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keratinocytes, macrophages and Langerhans cells is the 
basis of phototherapy of infl ammatory dermatoses11.
Broadband UVB involves 280–315 nm radiation, 
whereas lower wavelenghts can cause burns. In the past 
two decades, use of different fl uorescent tube coatings has 
allowed development of narrowband UVB with a narrow 
emission peak at 311 nm wavelength.
According to obtained results from several controlled 
studies, narrowband UVB phototherapy is more effi cient 
than conventional broadband UVB therapy, especially in 
the management of psoriasis, moderately severe atopic 
dermatitis and widespread vitiligo, emphasising therapeu-
tic onset and remission duration12,13.
Keratinocytes, circulating and cutaneous T-cells, neu-
trophils, monocytes, Langerhans cell, mast-cells and fi -
broblasts are susceptible to low doses of narrowband UVB 
and are thus more or less a selective target of the photons.
Ozawa et al. have shown that narrowband UVB causes 
greater depletion of T cells in psoriatic plaque and induces 
more rapid apoptosis of dermal T cells than broadband 
UVB2. Low doses of UVB light suppress mast-cell degran-
ulation, histamine release and prevent the UV-induced 
vasodilatation, being an important therapeutical mecha-
nism in atopic dermatitis and mastocytosis14. Immune 
suppression, alteration of cytokine expression, and cell 
cycle arrest may all contribute to the suppression of dis-
ease activity in psoriatic plaques.
Excimer laser emits monochromatic light at 308 nm 
wavelength and allows focused delivery of light to limited 
skin lesions and spares the surrounding uninvolved skin 
completely. According to several studies, patients with lo-
calized psoriatic plaques need fewer treatments with ex-
cimer laser in comparison to narrowband UVB photo-
therapy15.
The use of this laser is rather limited to treatment of 
localized plaques due to the small spot size, which makes 
targeting of large surface areas impractical16,17.
Westerhof and Nieuweboer-Krobotova reported for the 
fi rst time that follicular repigmentation in areas affected 
by vitiligo is improved by twice-weekly narrowband UVB 
for the maximum period of one year18. UV radiation en-
hances transcription of the tyrosinase gene (via microph-
thalmia-associated transcription factor), upregulates ex-
pression of proopiomelanocortin and its derivative peptides 
within keratinocytes, melanocytes and other cutaneous 
cells. In addition, increased activity of Rac1 (involved in 
dendrite formation), increased kinesin to dynein ratio, and 
upregulated expression of protease-activated receptor-2 
(PAR2; involved in melanosome transfer) stimulate mela-
nocytes dendricity and melanosome transport to kerati-
nocytes. UV radiation results in augmented anterograde 
transport by increased kinesin and decreased dynein ac-
tivity19,20.
The proposed mechanisms of UVB on cutaneous T-cell 
lymphomas include deterioration of epidermal Langerhans 
cell function and alterations in cytokine production and 
adhesion molecule expression by keratinocytes.
Narrowband UVB induces local and systemic immu-
nosuppressive effects which may particularly contribute 
to benefi cial effect of this light source16.
Ultraviolet A Therapy and Photochemotherapy
UVA light penetrates deeper into dermal structures, 
when compared to UVB light. UVA radiation carries less 
energy than UVB radiation, but due to its long wavelength 
penetrates the skin the deepest with as much as 50% 
reaching the dermis. Because of its longer mean wave-
length, UVA1 (340–400 nm) radiation penetrates more 
deeply into the skin than UVA2 (320–340 nm), and thus 
affects not only epidermal structures, but also mid and 
deep dermal components, especially blood vessels. UVA 
effects are dominated by indirect DNA damage caused by 
reactive oxygen species (ROS) such as singlet oxygen. 
DNA damage, activation of tumor suppressor genes, 
growth cytokines withdrawal (e.g. EGF, TGF-a, IGF, 
PDGF) and activation of cell-death mediators (e.g. TNF) 
induce apoptosis of the epidermal and dermal cells21. DNA 
damage due to UV radiation upregulates expression of the 
p53 tumor suppressor gene in the basal and suprabasal 
layers of epidermis22. Affected under p53, individual kera-
tinocytes will stop the cell cycle in G1 phase to allow time 
for DNA repair (pyrimidine dimer excision) before the cell 
enters into division phase or apoptosis of keratinocytes 
(»sunburn cells«) in case of irreparable DNA damage23.
The regulation of G1, G2 and M transitions involves 
three major protein families: cyclins, cyclin-dependent 
kinases (CDKs) and cyclin-dependent kinase inhibitors 
(CKIs). G1 arrest is mainly caused by p53-mediated activa-
tion of CKI which inhibits phosphorylation of retinoblas-
toma (Rb) protein. Dephosphorylated Rb protein blocks 
keratinocyte proliferation by binding to and thereby inac-
tivating transcription factor (E2F) required for transcrip-
tion of G1/S cyclins and cell cycle propagation. Rb dephos-
phorylation, at the G1 checkpoint blocks cell proliferation 
and causes G1 arrest24.
While inhibiting anti-apoptotic (Bcl-2) protein tran-
scription, p53 protein also activates transcription of pro-
apoptotic BAX protein. Caspases, apoptosis-related prote-
ases, are then activated by BAX resulting in nuclear DNA 
fragmentation and degradation of cellular structural pro-
teins such as laminin and actin21.
Edström et al. noted an increase of Ki67 positive cells 
in the epidermis and a slight increase of cyclin A positive 
cells after each cycle of UVA1 irradiation. This positivity 
indicates that there is an increased proportion of epider-
mal cells in the G1 phase which results in signifi cant ac-
anthosis25.
The mechanisms of enhanced keratinocyte apoptosis 
induced by PUVA (photochemotherapy) and UVA-1 differ. 
UVA1 irradiation induces both early apoptosis (protein 
synthesis independent) and late apoptosis of T-lympho-
cytes, that are relevant in the treatment of atopic derma-
titis and mycosis fungoides26. It may also reduce the num-
ber of Langerhans cells, mast-cells and regulatory 
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CD4+CD25+ T cells in the dermis in atopic dermatitis, 
and in cutaneous mastocytosis. Besides inducing apopto-
sis, photochemotherapy has been implicated in causing 
other immunomodulatory effects. Researchers have dis-
covered that PUVA decreases mast cell degranulation and 
histamine release. In addition, it has been shown that 
UVA1 induces increased expression of matrix metallopro-
teinase 1, a collagenase which reduces concentration of 
procollagen and collagen in treated lesions of localized 
scleroderma, resulting in softening and disappearance of 
sclerotic skin. Following the completed phototherapy and 
further regression of the sclerotic area continues25.
Photochemotherapy utilizes a combination of psoralens 
and UVA radiation. PUVA is used to treat numerous der-
matoses among which psoriasis, atopic dermatitis, vitiligo 
and cutaneous T-cell lymphoma are well-established indi-
cations27. Following many years of oral administration of 
psoralen with UVA, topical regimens such as bath and 
cream PUVA have been used more frequently. The usage 
of topical regimens avoids some of the systemic effects of 
oral psoralen, notably nausea and corneal uptake (protec-
tive glasses are required for 24 h after oral PUVA therapy) 
28,29. In the absence of UVA radiation, the psoralen inter-
calates between DNA base pairs. Absorption of photons in 
the UVA range results in the formation of unstable com-
plexes 3,4- or 4 ,́ 5´ -cyclobutane monoadduct with pyrim-
idine bases of native DNA. The 4 ,́ 5´ monoadducts can 
absorb a second photon and this reaction leads to the for-
mation of an interstrand cross-links in the double helix4.
Excited psoralens can also react with molecular oxy-
gen. Singlet oxygen, an excited state of molecular oxygen 
and part of the ROS, is generated during UVA exposure 
in the presence of photosensitizers. This reaction causes 
damage to cellular, mitochondrial, and nuclear mem-
branes by epidermal lipid peroxidation leading to massive 
calcium infl ux, extensive calcifi cation of the mitochondria, 
and cell death.
The conjunction of psoralens with epidermal DNA in-
hibits DNA replication in T-lymphocytes and keratino-
cytes and causes cell cycle arrest which leads to subse-
quent inhibition of cell proliferation in several dermatoses. 
Various mechanisms of action may be involved as well, 
since PUVA is also effective in nonproliferative diseases. 
Indeed psoralen photosensitization also alters expression 
of cytokines and cytokine receptors such as impairment 
of IL-2 production by T-lymphocytes, inhibition of epider-
mal growth factor receptor tyrosine kinase activity and 
inhibition of chemotactic activity of polymorphonuclear 
neutrophils in response to anaphylatoxin C5a30.
PUVA decreases expression of Th1/Th17 infl ammatory 
cytokines, specifi cally IFN-g, IL-12, and IL-23, within 
psoriatic lesions and serum31.
Apart from DNA, psoralens interact with RNA, pro-
teins and other cellular components and indirectly modify 
proteins and lipids via singlet oxygen-mediated reactions 
or by generating free radical production.
PUVA can reverse the pathologically altered patterns 
of keratinocyte differentiation markers and reduce the 
number of proliferating epidermal cells. PUVA strongly 
suppresses Infi ltrating lymphocytes, which varies depend-
ing on different T-cell subsets. PUVA is far more potent in 
induction of apoptosis in T-lymphocytes and antigen pre-
senting cells than in keratinocytes, which may explain its 
effi cacy in cutaneous lymphomas as well as in infl amma-
tory skin diseases such as psoriasis and atopic dermati-
tis32. According to Marks and Fox, PUVA could lead to 
apoptosis and modify expression of new oligopeptides in 
surface MHC molecules, which might be the cause why 
these cells have a higher level of antigenicity33.
In addition, PUVA also mediates the downregulation 
in expression of »homing receptors« (HECA) of epidermo-
tropic malignant T-cell thus PUVA serves as effective 
treatment modality in early-stage cutaneous T-cell lym-
phoma34.
Melanogenesis is also stimulated by PUVA. The pro-
cess involves the photoconjugation of psoralens to DNA in 
melanocytes followed by mitosis and subsequent prolif-
eration of melanocytes, which leads to repopulation of the 
epidermis, increased formation and melanization of mela-
nosomes, enhanced transfer of melanosomes to keratino-
cytes, and increased synthesis of tyrosinase via stimula-
tion of cAMP activity18–20.
Extracorporeal Photopheresis
Extracorporeal photopheresis (ECP) is a technique 
which uses UVA irradiation of leukocyte-enriched blood 
in the presence of psoralen. Photosensitizing agent can be 
administered orally or directly to the leukocyte/plasma 
concentrate, which is then subsequently irradiated outside 
the body in the process of plasmapheresis and returned to 
the circulation. It is an effective therapeutic regimen for 
erythrodermic cutaneous T-cell lymphoma. This tech-
nique is very potent in induction of apoptosis in T-lympho-
cytes and modifi cation of lymphocyte cytokine production.
Knobler et al. posed a hypothesis that reinfusion of 
ECP-treated lymphocytes induces autovaccination against 
the pathogenic T-cell clones35.
Conclusion
Despite the introduction of numerous potent bioengi-
neered systemic medications in the fi eld of dermatology, 
phototherapy remains established and often preferred op-
tion for the most common dermatoses. Still the actual 
pathways underlying phototherapy in most dermatoses 
are not known in details, therefore further studies on both 
clinical and basic photoimmunology will be needed to 
reach these goals.
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KORISNOST FOTOTERAPIJE U LIJEČENJU DERMATOLOŠKIH BOLESTI
S A Ž E T A K 
Fototerapija označava upotrebu ultraljubičastog (UV) svjetla u liječenju nekoliko bolesti kože, a koriste se različite 
valne duljine ultraljubičastog zračenja. Trenutno, fototerapija obuhvaća širokospektralnu UVB (290–320 nm), uskospek-
tralnu UVB (311–313 nm), 308 nm excimer laser, UVA 1 (340–400 nm), psoralen plus UVA (PUVA) i ekstrakorporalnu 
fotokemoterapiju – fotoferezu. Međudjelovanje različitih fotobioloških mehanizama za sada nije u potpunosti razjašnjeno. 
Veliki broj bolesti kože ima dobar terapijski odgovor na fototerapiju, a neke od najvažnijih indikacija su: psorijaza, at-
opijski dermatitis, T-stanični limfom kože, cirkumskriptna sklerodermija i vitiligo. UVB zračenje prvenstveno djeluje 
na strukture epidermisa i papilarnog dermisa, dok UVA djeluje na papilarni i retikularni dermis, a osobito na krvne 
žile. UVB zračenje apsorbiraju endogene kromofore, poput DNA jezgre, čime se potiče cijeli niz biokemijskih reakcija. 
Apsorpcija UV zračenja od strane DNA dovodi do stvaranja fotospojeva koji dovode do smanjene sinteze DNA. Pored ovog 
učinka, UV zračenje dovodi do otpuštanja prostaglandina i citokina koji imaju važan učinak u supresiji imunološkog 
odgovora. UV zračenje smanjuje broj Langerhansovih stanica, T-limfocita i mastocita u dermisu. Također djeluje na 
molekule u citoplazmi i na staničnoj membrani. Najvažniji mehanizmi fototerapije su apoptoza, lokalna i sistemna imu-
nosupresija, te promjena ekspresije i sekrecije citokina. PUVA je oblik fotokemoterapije kod kojeg se koriste psoraleni i 
UVA zračenje. Psoraleni stvaraju unakrsne veze s DNA, inhibiraju replikaciju DNA i uzrokoju zaustavljanje staničnog 
ciklusa. Nakon izlaganja UVA zračenju psoraleni mijenjaju ekspresiju citokina i njihovih receptora. Osim navedenog, 
psoraleni djeluju na RNA, te ostale strukture stanice i putem slobodnih kisikovih radikala utječu na oštećenje proteina 
i lipida. PUVA snažno utječe na supresiju limfocita s različitim učinkom na različite podvrste T-limfocita. Psoraleni i 
UVA zračenje potiču i melanogenezu. Ekstrakorporalna fotofereza je metoda koja se primjenjuje u liječenju eritrodermij-
skog stadija limfoma kože. Ova metoda snažno potiče apoptozu T-limfocita. Unatoč primjeni različitih učinkovitih si-
stemnih i bioloških lijekova u dermatologiji, fototerapija ostaje pouzdana terapija izbora u liječenju različitih bolesti kože.
